Research advances in apatinib combined with transcatheter arterial embolization in the treatment of hepatocellular carcinoma / 临床肝胆病杂志

ABSTRACT

Hepatocellular carcinoma (HCC) is a common malignant tumor that threatens the health of all mankind, and its incidence and mortality rates keep increasing in recent years. Most patients are in the advanced stage at the time of confirmed diagnosis and are unable to undergo potential therapeutic surgery. Transcatheter arterial chemoembolization (TACE) and the anti-angiogenic drug apatinib are two palliative treatments for HCC. At present, apatinib combined with TACE is still a new treatment method for HCC in clinical practice, and there are still controversies over its efficacy and safety, which needs further studies. This article reviews the research advances in apatinib combined with TACE in the treatment of HCC.